Literature DB >> 15507650

Human immunodeficiency virus type 1 (HIV-1)-specific CD4+ T cells that proliferate in vitro detected in samples from most viremic subjects and inversely associated with plasma HIV-1 levels.

Eli Boritz1, Brent E Palmer, Cara C Wilson.   

Abstract

Diminished in vitro proliferation of human immunodeficiency virus type 1 (HIV-1)-specific CD4+T cells has been associated with HIV-1 viremia and declining CD4+ T-cell counts during chronic infection. To better understand this phenomenon, we examined whether HIV-1 Gag p24 antigen-induced CD4+ T-cell proliferation might recover in vitro in a group of subjects with chronic HIV-1 viremia and no history of antiretroviral therapy (ART). We found that depletion of CD8+ cells from peripheral blood mononuclear cells (PBMC) before antigen stimulation was associated with a 6.5-fold increase in the median p24-induced CD4+ T-cell proliferative response and a 57% increase in the number of subjects with positive responses. These p24-induced CD4+ T-cell proliferative responses from CD8-depleted PBMC were associated with expansion of the numbers of p24-specific, gamma interferon (IFN-gamma)-producing CD4+ T cells. Among the 20 viremic, treatment-naive subjects studied, the only 5 subjects lacking proliferation-competent, p24-specific CD4+ T-cell responses from CD8-depleted PBMC showed plasma HIV-1 RNA levels > 100,000 copies/ml. Furthermore, both the magnitude of p24-induced CD4+ T-cell proliferative responses from CD8-depleted PBMC and the frequency of p24-specific, IFN-gamma-producing CD4+ T cells expanded from CD8-depleted PBMC were associated inversely with plasma HIV-1 RNA levels. Therefore, proliferation-competent, HIV-1-specific CD4+ T cells that might help control HIV-1 disease may persist during chronic, progressive HIV-1 disease except at very high levels of in vivo HIV-1 replication.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15507650      PMCID: PMC525069          DOI: 10.1128/JVI.78.22.12638-12646.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Limiting dilution analysis (LDA) of cells responding to recombinant interleukin-2 without previous stimulation: evidence that all responding cells are lymphokine-activated potent effectors.

Authors:  H Vie; M Bonneville; P Sondermeyer; J F Moreau; J P Soulillou
Journal:  Immunology       Date:  1986-03       Impact factor: 7.397

Review 2.  Interleukin-2, a pro-autoimmune lymphokine that interferes with post-deletional tolerance.

Authors:  G Kroemer; C Martínez
Journal:  Semin Immunol       Date:  1992-06       Impact factor: 11.130

3.  CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection.

Authors:  M Matloubian; R J Concepcion; R Ahmed
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

4.  Effects of sustained HIV-1 plasma viremia on HIV-1 Gag-specific CD4+ T cell maturation and function.

Authors:  Brent E Palmer; Eli Boritz; Cara C Wilson
Journal:  J Immunol       Date:  2004-03-01       Impact factor: 5.422

5.  A factor from CD8 cells of human immunodeficiency virus-infected patients suppresses HLA self-restricted T helper cell responses.

Authors:  M Clerici; E Roilides; C S Via; P A Pizzo; G M Shearer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

6.  Association of T cell proliferative responses and phenotype with virus control in chronic progressive HIV-1 disease.

Authors:  Uma Malhotra; Ronald J Bosch; Ellen Chan; Rui Wang; Margaret A Fischl; Ann C Collier; M Juliana McElrath
Journal:  J Infect Dis       Date:  2004-01-16       Impact factor: 5.226

7.  The interleukin-2 receptor subunit expression and function on peripheral blood lymphocytes from HIV-infected and control persons.

Authors:  G Vanham; L Kestens; J Vingerhoets; G Penne; R Colebunders; M Vandenbruaene; J Goeman; J L Ceuppens; K Sugamura; P Gigase
Journal:  Clin Immunol Immunopathol       Date:  1994-04

8.  Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy.

Authors:  Alexandre Harari; Stéphanie Petitpierre; Florence Vallelian; Giuseppe Pantaleo
Journal:  Blood       Date:  2003-09-04       Impact factor: 22.113

9.  HIV-1 replication is controlled at the level of T cell activation and proviral integration.

Authors:  M Stevenson; T L Stanwick; M P Dempsey; C A Lamonica
Journal:  EMBO J       Date:  1990-05       Impact factor: 11.598

10.  HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity.

Authors:  Souheil-Antoine Younes; Bader Yassine-Diab; Alain R Dumont; Mohamed-Rachid Boulassel; Zvi Grossman; Jean-Pierre Routy; Rafick-Pierre Sekaly
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

View more
  10 in total

1.  In vitro naïve T cell proliferation failure predicts poor post-immunization responses to neoantigen, but not recall antigens, in HIV-infection.

Authors:  Benigno Rodriguez; Hernan Valdez; Christoph G Lange; Robert Asaad; Kathy Medvik; Scott F Sieg
Journal:  Clin Immunol       Date:  2010-05-15       Impact factor: 3.969

2.  Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial.

Authors:  Jonathan Z Li; Zabrina L Brumme; Chanson J Brumme; Hongying Wang; John Spritzler; Michael N Robertson; Michael M Lederman; Mary Carrington; Bruce D Walker; Robert T Schooley; Daniel R Kuritzkes
Journal:  J Infect Dis       Date:  2011-04-01       Impact factor: 5.226

3.  CD4+ T cell targeting of human immunodeficiency virus type 1 (HIV-1) peptide sequences present in vivo during chronic, progressive HIV-1 disease.

Authors:  Eli Boritz; Eric L Rapaport; Thomas B Campbell; John R Koeppe; Cara C Wilson
Journal:  Virology       Date:  2006-12-13       Impact factor: 3.616

4.  Characterization of HIV-1 Gag-specific T cell responses in chronically infected Indian population.

Authors:  S Kaushik; M Vajpayee; N Wig; P Seth
Journal:  Clin Exp Immunol       Date:  2005-11       Impact factor: 4.330

5.  Design and preclinical development of a recombinant protein and DNA plasmid mixed format vaccine to deliver HIV-derived T-lymphocyte epitopes.

Authors:  Leslie E Walker; Lo Vang; Xuefei Shen; Brian D Livingston; Penny Post; Alessandro Sette; C Steven Godin; Mark J Newman
Journal:  Vaccine       Date:  2009-09-26       Impact factor: 3.641

6.  Dynamics of T-cell responses and memory T cells during primary simian immunodeficiency virus infection in cynomolgus macaques.

Authors:  Ingrid Karlsson; Benoît Malleret; Patricia Brochard; Benoît Delache; Julien Calvo; Roger Le Grand; Bruno Vaslin
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

7.  IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells.

Authors:  Mark A Brockman; Douglas S Kwon; Daniel P Tighe; David F Pavlik; Pamela C Rosato; Jennifer Sela; Filippos Porichis; Sylvie Le Gall; Michael T Waring; Kristin Moss; Heiko Jessen; Florencia Pereyra; Daniel G Kavanagh; Bruce D Walker; Daniel E Kaufmann
Journal:  Blood       Date:  2009-04-13       Impact factor: 22.113

Review 8.  Relevance of studying T cell responses in SIV-infected rhesus macaques.

Authors:  Laura E Valentine; David I Watkins
Journal:  Trends Microbiol       Date:  2008-10-27       Impact factor: 17.079

9.  Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial.

Authors:  Jonathan Z Li; Chanson J Brumme; Michael M Lederman; Zabrina L Brumme; Hongying Wang; John Spritzler; Mary Carrington; Kathleen Medvik; Bruce D Walker; Robert T Schooley; Daniel R Kuritzkes
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

10.  Induction of a virus-specific effector-memory CD4+ T cell response by attenuated SIV infection.

Authors:  Marie-Claire Gauduin; Yi Yu; Amy Barabasz; Angela Carville; Mike Piatak; Jeffrey D Lifson; Ronald C Desrosiers; R Paul Johnson
Journal:  J Exp Med       Date:  2006-11-20       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.